Kenan Distinguished Professor
Area of Interest
Our broad research interest centers on understanding the molecular basis of human carcinogenesis. Specifically, our research studies have dealt with three distinct aspects of Ras family oncogene proteins and on the discovery of novel oncogenes involved in specific human cancers.
First, we are interested in deciphering the increasingly complex nature of signal transduction pathways that mediate the oncogenic actions of Ras.
Second, we now know that the three Ras proteins represent only a mere subset of a large superfamily of Ras-related proteins. Mammalian members of this family number more than 60, with more likely to be discovered. Since Ras-related proteins share strong sequence and biochemical similarities with Ras proteins, a logical question is whether the aberrant function of any other members of this superfamily are also oncogene proteins involved in cancer development. Much of our current interest has centered on members of the Rho family of Ras-related proteins, which function as regulators of a wide spectrum of cellular processes that include actin cytoskeletal organization, gene expression and cell cycle progression. Recent studies by us and others have revealed that quite a diverse collection of oncogene proteins (including Ras) cause transformation, in part, by deregulating the function of Rho family proteins. It is generally believed that Rho family proteins may serve as key players in promoting the invasive and malignant properties of tumor cells. How Rho proteins contribute to Ras transformation, and what signaling pathways connect Ras with Rho, are questions that we are pursuing in our studies.
Third, we are involved in drug discovery efforts to target Ras for cancer treatment.
Awards and Honors
- Established the importance of aberrant Rho family GTPase activation and signaling in human oncogenesis.
- Determined that Ras utilizes signaling pathways (e.g., Ral GEF and Tiam1), other than the ERK mitogen-activated protein kinase cascade, to mediate oncogenesis in human cells.
- Determined that oncogenic Ras signaling is cell context dependent and that transformation of rodent versus human cells involves distinct signaling mechanisms.
News and Stories
Pancreatic Cancer Center of Excellence to leverage research and clinical care innovations for patients
The Pancreatic Cancer Center of Excellence brings together researchers, clinicians and staff to provide excellent multidisciplinary patient care and generate research discoveries that can be translated into new, more effective approaches for pancreatic cancer.
Advancing pancreatic cancer research and care
Pancreatic cancer is an extremely challenging cancer to treat and has an increasing incidence in the United States. Fortunately, pancreatic cancer research is being conducted at UNC Lineberger.
Der named AAAS Fellow
The honor recognizes Der's contributions to cancer research. His lab's recent findings on pancreatic cancer have led to clinical studies of a new treatment.
Researchers find KRAS gene mutation differences have implications for pancreatic cancer treatment
The KRAS gene is commonly mutated in cancer. In the journal Cancer Discovery, researchers led by Channing Der, PhD, and Aaron Hobbs, PhD, reported details of the role of the KRAS G12R mutation in pancreatic cancer, and therapeutic strategies that might work for this mutation type. By studying unique differences in DNA mutations within the same gene, researchers are working to uncover the mutation-specific mechanisms that drive cancerous growth.